Neoadjuvant Therapy Clinical Trial
Official title:
A Prospective Randomized Phase II Trial of CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for Microsatellite Stable Locally Advanced Rectal Cancer (TORCH-iTNT)
TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1). Group A receives 6 cycles of Toripalimab combined with CAPOX (ToriCAPOX). Group B receives SCRT (25Gy/5Fx) followed by 6 cycles of ToriCAPOX. TME surgery is scheduled after TNT while a watch and wait (W&W) option can be applied to patients achieving clinical complete response (cCR). The primary endpoint is complete response (CR, pathological complete response [pCR] plus cCR) rate. The secondary endpoints include the grade 3-4 acute adverse effects (AE) rate, anal preservation rate, 3-year DFS rate, etc.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05996484 -
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04520737 -
Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases
|
N/A | |
| Recruiting |
NCT06138496 -
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
|
Phase 2 | |
| Not yet recruiting |
NCT05983094 -
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04440982 -
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT04028375 -
Study of CT and MR in the Gastric Cancer
|
||
| Active, not recruiting |
NCT03192735 -
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04588987 -
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
|
Phase 2 | |
| Not yet recruiting |
NCT05993858 -
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
|
Phase 2 | |
| Active, not recruiting |
NCT04666090 -
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04848454 -
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
|
Phase 2 | |
| Recruiting |
NCT04062058 -
A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT06124378 -
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06125223 -
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
|
||
| Recruiting |
NCT05371197 -
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06212440 -
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy
|
N/A | |
| Completed |
NCT03178032 -
Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
| Recruiting |
NCT02769104 -
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04986306 -
The Validation of Sentinel Lymph Node Biopsy After Neo-adjuvant Chemotherapy in Breast Cancer Patients
|